ストックスクリーナーアプリを入手
19.90
5.06%
-1.06
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from B. Riley - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5%What's Next? - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Outperform Rating from Royal Bank of Canada - MarketBeat
Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating - Marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript - MSN
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results, Misses Expectations By $0.97 EPS - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals: Promising Pipeline Amidst Cautious Financial Outlook Warrants Hold Rating - TipRanks
Arrowhead Pharmaceuticals IncOn February 10 - Smartkarma
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by abrdn plc - MarketBeat
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down After Earnings Miss - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - BioSpace
Arrowhead Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy Rating - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts - Investing.com
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines -- Shares Down After Hours - Marketscreener.com
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Reports Q1 Revenue $2.5M -February 10, 2025 at 04:16 pm EST - Marketscreener.com
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Arrowhead Pharmaceuticals Q1 2025 Earnings Preview - MSN
Arrowhead and Sarepta close $500 million licensing deal By Investing.com - Investing.com Australia
ARWR Seals Mega-Deal: $825M Cash Infusion Plus Billions in Potential Milestone Payments - StockTitan
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns - Seeking Alpha
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):